Sichuan Kelun Pharma has announced its intention to acquire stakes in two pharmaceutical companies, one based in Guangxi and another in Changshu.

"It will acquire the remaining 20% stake in the Guangxi-based company for $5.3m to obtain 100% ownership, and 35% in the Changshu-based biopharmaceutical company."

It will acquire the remaining 20% stake in the Guangxi-based company for $5.3m to obtain 100% ownership, and 35% in the Changshu-based biopharmaceutical company.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

French pre-clinical services provider CiToxLAB Group has completed the acquisition of Canadian company, AccelLAB, with the aim of strengthening its position in the non-clinical contract research market and extending its services portfolio to medical devices.

The target company is a pre-clinical contract research organisation that employs approximately 100 people.

CiToxLab operates in France, Canada, Hungary and Denmark with a total of 1,000 staff as a result of the acquisition.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact